Gynaecomastia: The Anastrozole Paradox

  title={Gynaecomastia: The Anastrozole Paradox},
  author={Davide Bedognetti and Alessandra Rubagotti and Gabriele Zoppoli and Francesco Boccardo},
  journal={Journal of Pediatric Endocrinology and Metabolism},
  pages={205 - 206}
Recently, Mauras et al. published the results of a clinical trial evaluating the pharmacokinetics of oral anastrozole (an aromatase inhibitor) in adolescent males with gynaecomastia. The authors evaluated 42 boys (11-15 years old) with early onset gynaecomastia (4:5-10.5 months) treated with anastrozole (1 mg daily) for 6 months. Mauras and coworkers found that anastrozole had rapid absorption and slow elimination kinetics, and caused testosterone/oestradiol to increase, proving its aromatase… Expand
1 Citations
Drug‐Induced Gynecomastia
Antiandrogens, protease inhibitors, and nucleoside reverse transcriptase inhibitors are the most common drug causes of gynecomastia, whereas first‐generation antipsychotics, spironolactone, verapamil, and cimetidine are less common causes. Expand


Pharmacokinetics and pharmacodynamics of anastrozole in pubertal boys with recent-onset gynecomastia.
Anastrozole is a potent aromatase inhibitor in adolescent males, with rapid absorption and slow elimination kinetics after oral dosing and breast reduction in the cohort; this deserves further study. Expand
Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia.
Inhibition of estrogen receptor action in the breast appears to be safe and effective in reducing persistent pubertal gynecomastia, with a better response to raloxifene than to tamoxifen. Expand
Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole
Tamoxifen, but not anastrozole, significantly reduced the incidence of gynecomastia/breast pain when used prophylactically and therapeutically and any impact on cancer control is still to be investigated. Expand
Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: a randomized, double-blind, placebo-controlled trial.
In patients with pubertal gynecomastia, no significant difference in the percentage of patients with a 50% or greater reduction in total breast volume, as calculated from ultrasonography measurements, was demonstrated between the anastrozole and placebo groups. Expand
Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer.
Anastrozole did not significantly reduce the incidence of bicalutamide-induced gynecomastia and breast pain and tamoxifen was effective, without increasing adverse events, at least in the short-term follow-up, which supports the need for a larger study to determine any effect on mortality. Expand
The Effect of Tamoxifen on Sex Hormone Binding Globulin in Adolescents with Pubertal Gynecomastia
The relationship between sex hormone binding globulin (SHBG) and pubertal gynecomastia in 21 adolescents evaluated longitudinally is investigated and it is suggested that serum SHBG is increased by tamoxifen treatment in male adolescents. Expand
An open, randomised, multicentre, phase 3 trial comparing the efficacy of two tamoxifen schedules in preventing gynaecomastia induced by bicalutamide monotherapy in prostate cancer patients.
It is demonstrated that tamoxifen 20mg/wk is inferior to tamoxIFen 20 mg/d in preventing the incidence and severity of bicalutamide-induced breast events. Expand
Influence of bicalutamide with or without tamoxifen or anastrozole on insulin-like growth factor 1 and binding proteins in prostate cancer patients.
The concurrent administration of tamoxifen and bicalutamide reduces the synthesis and bioavailability of IGF-1 and increased binding protein levels might exert antiproliferative and proapoptotic effects on prostate cancer cells, independently of the IGF- 1/IGF receptor-mediated survival system. Expand
Clinical practice. Gynecomastia.
Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: a randomized, double-blind, placebocontrolled trial
  • J Clin Hndocrinol Metab
  • 2004